Research
Hormonal
GLP-1 RA users had higher rates of type 2 diabetes (55.6% versus 29.5%) compared to nonusers.
Understanding the diabetes status of patients may inform perioperative management strategies.
StrongSupportsmedium confidence
GLP-1 RA users had higher rates of type 2 diabetes (55.6% versus 29.5% [ P = 0.01])
Why this rating
Based on a retrospective analysis of 373 patients.
Source
Perioperative GLP-1 Receptor Agonist Use and Surgical Outcomes in Nonbariatric Abdominal Panniculectomy: A 10-Year Retrospective Analysis
Zachary A Koenig et al. · Plastic & Reconstructive Surgery · 2025
DOI 10.1097/prs.0000000000012405
cohort · n=373Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →